Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MEP1B | Q16820 | 6/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5620841 | 0.93 | RXFP1 (0.40) | MRGPRX4MEN1KMT2AMEP1BRXFP1 | |
| SCHEMBL5620864 | 0.90 | ROCK2 (0.39) | MEN1KMT2ARXFP1SMN1; SMN2TDP1 | |
| SCHEMBL5620425 | 0.88 | GYS1 (0.43) | MEN1KMT2ARXFP1TP53TDP1 | |
| SCHEMBL5622717 | 0.88 | HTR1A (0.43) | MEN1KMT2ARXFP1TDP1 | |
| SCHEMBL5620496 | 0.87 | MEN1 (0.37) | MEN1KMT2ARXFP1SMN1; SMN2FABP4 | |
| SCHEMBL5621209 | 0.87 | MEN1 (0.38) | MEN1KMT2ARXFP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5622444 | 0.87 | ACHE (0.40) | MEN1KMT2ARXFP1SMN1; SMN2FABP4 | |
| SCHEMBL5621543 | 0.87 | FYN (0.42) | SMN1; SMN2RAB9A | |
| SCHEMBL5620924 | 0.87 | HTR1A (0.46) | MEN1KMT2ARXFP1TDP1 | |
| SCHEMBL5623392 | 0.87 | CASR (0.40) | MRGPRX4KMT2ATP53SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244738-B2 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2007-07-17 | — | — | US | claimed |
| US-20050038016-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC | 2005-02-17 | — | — | US | claimed |
| US-20070265446-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | CONNOLLY TERRENCE J | 2007-11-15 | — | — | US | disclosed |
| US-20070265446-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | CONNOLLY TERRENCE J | 2007-11-15 | — | — | US | disclosed |
| US-20070265446-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | CONNOLLY TERRENCE J | 2007-11-15 | — | — | US | disclosed |
| US-7244738-B2 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244738-B2 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244738-B2 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2007-07-17 | — | — | US | disclosed |
| CN-1845924-A | Arylamine-substituted quinazolinone compounds | HOFFMANN LA ROCHE (CH) | 2006-10-11 | — | — | CN | disclosed |
| US-20050038016-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265446-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRA1A, ADRA1B | MRGPRX4 131/4885MEN1 3414/4885KMT2A 2952/4885 |
| US-20050038016-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRA1A, ADRA1B | MRGPRX4 131/4885MEN1 3414/4885KMT2A 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.